3,270 Shares in argenex SE $ARGX Bought by SWS Partners

Key Points

• SWS Partners purchased 3,270 shares of argenex SE for roughly $1.8 million, indicating growing institutional interest in the company.
• Analysts have a generally positive outlook on argenex, with an average rating of "Buy" and a consensus target price of $789.20.
• In its recent earnings report, argenex exceeded expectations with $3.74 EPS and reported revenue of $866.79 million for the quarter.

SWS Partners acquired a new position in shares of argenex SE (NASDAQ:ARGX - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 3,270 shares of the company's stock, valued at approximately $1,803,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Millennium Management LLC raised its position in argenex by 316.9% in the 1st quarter. Millennium Management LLC now owns 268,604 shares of the company's stock valued at $158,977,000 after purchasing an additional 204,180 shares during the last quarter. BNP Paribas Financial Markets increased its stake in argenex by 1,203.4% in the first quarter. BNP Paribas Financial Markets now owns 133,359 shares of the company's stock valued at $78,931,000 after purchasing an additional 123,127 shares during the period. Braidwell LP increased its stake in argenex by 99.2% in the first quarter. Braidwell LP now owns 160,849 shares of the company's stock valued at $95,201,000 after purchasing an additional 80,083 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of argenex by 215.8% in the first quarter. Assenagon Asset Management S.A. now owns 110,390 shares of the company's stock valued at $65,336,000 after buying an additional 75,435 shares during the last quarter. Finally, Lord Abbett & CO. LLC boosted its stake in shares of argenex by 33.2% during the first quarter. Lord Abbett & CO. LLC now owns 274,700 shares of the company's stock worth $162,585,000 after buying an additional 68,498 shares during the period. Institutional investors and hedge funds own 60.32% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ARGX. Piper Sandler increased their price objective on argenex from $750.00 to $820.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 26th. Stifel Nicolaus set a $882.00 price target on argenex in a report on Thursday, September 18th. Zacks Research upgraded shares of argenex from a "hold" rating to a "strong-buy" rating in a research report on Monday, September 22nd. Wells Fargo & Company upped their price objective on shares of argenex from $741.00 to $756.00 and gave the stock an "overweight" rating in a research report on Thursday, July 31st. Finally, Wedbush restated an "outperform" rating and issued a $800.00 target price on shares of argenex in a research note on Monday, August 25th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $789.20.

argenex Stock Performance

argenex stock opened at $711.62 on Monday. The company has a market cap of $43.55 billion, a P/E ratio of 36.49, a price-to-earnings-growth ratio of 0.78 and a beta of 0.41. argenex SE has a one year low of $510.05 and a one year high of $779.03. The business has a fifty day moving average of $684.59 and a two-hundred day moving average of $615.88.

argenex (NASDAQ:ARGX - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, topping analysts' consensus estimates of $2.84 by $0.90. argenex had a net margin of 40.98% and a return on equity of 21.06%. The business had revenue of $866.79 million for the quarter, compared to analysts' expectations of $776.82 million. Sell-side analysts predict that argenex SE will post 3.13 EPS for the current year.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.